Hormone therapy in postmenopausal women and risk of endometrial hyperplasia (Q24241713)

26 October 2023

3

Jane Marjoribanks

Jane

Marjoribanks

1 reference

26 October 2023

4

Anne Lethaby

Anne

Lethaby

1 reference

26 October 2023

5

Martha Hickey

Martha

Hickey

1 reference

26 October 2023

Helen Roberts

2

Helen

Roberts

1 reference

26 October 2023

1

Susan Furness

Sue

Furness

1 reference

19370558

Cochrane Database of Systematic Reviews

26 October 2023

language of work or name

1 reference

15 April 2009

0 references

published in

0 references

cites work

Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17beta-estradiol/trimegestone versus 1 or 2 mg 17beta-estradiol/norethisterone acetate in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17beta-estradiol and trimegestone versus two regimens combining 1 or 2 mg 17beta-estradiol and norethisterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy: a randomized comparative dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Comparison of the difference in histopathology and cell cycle kinetics among the postmenopausal endometrium treated with different progestins in sequential-combined hormone replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomised comparison of low and standard doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

A comparative 2-year study of the effects of sequential regimens of 1 mg 17beta-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17beta-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a two-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional-dose regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Hormone replacement therapy: effect of progestin dose and time since menopause on endometrial bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Continuous combined piperazine oestrone sulphate and medroxyprogesterone acetate hormone replacement therapy--a study of bleeding pattern, endometrial response, serum lipid and bone density changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy. The Ogen/Provera Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

A prospective randomized controlled study comparing two doses of gestodene in cyclic combined HRT preparations on endometrial physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Postmenopausal hormone use following a 3-year randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Recruitment of postmenopausal women in the PEPI Trial. Postmenopausal Estrogen/Progestin Interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Baseline characteristics of the PEPI participants. Postmenopausal Estrogen/Progestin Interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

A randomized, double-blind, placebo-controlled, multicenter study that assessed the endometrial effects of norethindrone acetate plus ethinyl estradiol versus ethinyl estradiol alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate therapy regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Intermittent progestin administration as part of hormone replacement therapy: long-term comparison between estradiol 1 mg combined with intermittent norgestimate and estradiol 2 mg combined with constant norethisterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Bleeding patterns and endometrial histology during administration of low-dose estradiol sequentially combined with dydrogesterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

The effects of oral estriol on the endometrium in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Effects of two years' estrogen-gestagen replacement on climacteric symptoms and gonadotropins in the early postmenopausal period

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

The comparison of bleeding patterns with high-dose and low-dose hormone replacement therapy in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Desogestrel in hormone replacement therapy: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Bleeding patterns during continuous combined estrogen-progestogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Estrogen Replacement Therapy II: A Prospective Study in the Relationship to Carcinoma and Cardiovascular and Metabolic Problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone acetate or with 17beta-estradiol and norethindrone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Effects of trimonthly progestin administration on the endometrium in elderly postmenopausal women who receive hormone replacement therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Unopposed estradiol therapy in postmenopausal women: results from two randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

17beta-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

The effect of a change in the dose of trimegestone on the pattern of bleeding in estrogen-treated post-menopausal women: 6 month extension of a dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Trimegestone in a low-dose, continuous-combined hormone therapy regimen prevents bone loss in osteopenic postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

A study of combined continuous ethinyl estradiol and norethindrone acetate for postmenopausal hormone replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Endometrial cancer and estrogen use. Report of a large case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Endometrium Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

A risk-benefit assessment of estrogen therapy in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

HRT: developments in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Estrogen and endometrial carcinoma. An independent pathology review supporting original risk estimate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Hormone replacement therapy and endometrial cancer risk: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Treatment of menopausal symptoms: what shall we do now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Nestorone: a progestin with a unique pharmacological profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Estrogens and Endometrial Cancer in a Retirement Community

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Progestogens in combined oral contraceptives for contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. II. An assessment of treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Estrogen-Progestin Replacement Therapy and Endometrial Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

21 January 2018

Managing the menopause.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Association of Exogenous Estrogen and Endometrial Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Combined continuous hormone replacement therapy: a critical review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Controversies concerning the safety of estrogen replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Increased Risk of Endometrial Carcinoma among Users of Conjugated Estrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestagen replacement therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestin regimens

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women: placebo-controlled trial of its gynecologic and metabolic actions.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Hormone replacement therapy after transcervical resection of the endometrium

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Rationale, design, and conduct of the PEPI Trial. Postmenopausal Estrogen/Progestin Interventions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. Introduction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Physical and laboratory measurements in the PEPI Trial Postmenopausal Estrogen/Progestin Interventions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Benefits and risks of different hormonal replacement therapies in post-menopausal women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

A novel statistical approach to analysis of bleeding patterns during continuous hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Secretory endometrial protein PP14 in serum from post-menopausal women receiving continuous combined oestradiol-cyproterone acetate: correlation with serum hormone concentrations and bleeding patterns

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

17 beta-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Is bleeding a predictor of endometrial hyperplasia in postmenopausal women receiving hormone replacement therapy? Menopause Study Group (United States, Italy, Netherlands, Switzerland, Belgium, Germany, and Finland

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Progestational effects of combinations of gestodene on the postmenopausal endometrium during hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Endometrial hyperplasia in women on cyclic or continuous estrogen regimens

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Comparison of two continuous combined estrogen progestogen regimens in postmenopausal women: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. The FemHRT Study Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Norethindrone acetate and estradiol-induced endometrial hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

HRT and exercise: effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Effects of Estrogens and Progestins on the Biochemistry and Morphology of the Postmenopausal Endometrium

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy. The Scandinavian LongCycle Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Optimizing continuous-combined hormone replacement therapy for postmenopausal women: a comparison of six different treatment regimens

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Serum placental protein 14 (PP14) reflects endometrial status during hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

The behavior of endometrial hyperplasia: a prospective study. Endometrial Hyperplasia Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Comparison of four continuously administered progestogen plus oestradiol combinations for climacteric complaints

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Piperazine oestrone sulphate and interrupted norethisterone: effects on the postmenopausal endometrium

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: Update of safety and quality-of-life findings

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

The Effects of Cyclical Oestrogen Therapy and Sequential Oestrogen/Progestogen Therapy on the Endometrium of Post-Menopausal Women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest for continuous combined hormone replacement therapy in postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000402.PUB3

7 January 2021

10.1002/14651858.CD000402.PUB3

Identifiers

DOI

0 references

Fatcat ID

release_oktphgpssrb7nha2qv7tmyzm7u

0 references